Dasatinib

目录号：S1021 别名： BMS-354825

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献76篇：

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )
Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )
Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )
Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M1nxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{O2XFczKGh?	MWfEUXNQ	M2fuR2lEPTB;MD6wNFAxPyEQvF2=	NH7q[GkyPzl3NkC4NC=>
K562	NEfyUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWG3NkBp	MVzEUXNQ	MnLwTWM2OD1yLkCwNUDPxE1?	NVfoWIN[OTd7NU[wPFA>
M07e	M13Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3j4eFczKGh?	MY\EUXNQ	Ml;zTWM2OD1yLkCwNVIh\|ryP	NHroUFUyPzl3NkC4NC=>
ALL3	NYDYOWh2S3m2b4TvfIlkKEG\|c3H5	MkfONE4y\|ryP	MUi3NkBp	MULEUXNQ	NET0PWtKSzVyPUCuNFAxPCEQvF2=	NFjzS\|EyQTh6OUW0NC=>
CML	M1TW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUOyNEBucW5?	M3THNWROW09?	Mnj0TWM2OD1yLkCwNUDPxE1?	NGToUZIyQTJzOUCxOi=>
BA/F3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXXte3ZTPzJiaB?=	MkTnSG1UVw>?	NUjZWJFDUUN3ME22MlU5QSEQvF2=	NVXY[ItHOjNyOEi2OFQ>
BA/F3	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXPTZc4OiCq	MWPEUXNQ	NVfJSlBIUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	MVSyN\|A5QDZ2NB?=
BA/F3	M{Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYm3NkBp	M4fk[GROW09?	NE\kPWlKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2\|ryP	MU[yN\|A5QDZ2NB?=
BA/F3	M1fGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkOxO\|IhcA>?	MVTEUXNQ	NEjrNFFKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=	MXqyN\|A5QDZ2NB?=
BA/F3	NWX0epc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUHzPZp5PzJiaB?=	NF;XS5dFVVOR	NX\PdGw{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2=	NGLCNGozOzNyMUewNy=>
BA/F3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnxe3M4OiCq	NWrMc\|lSTE2VTx?=	MYrJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>?	MYOyN\|MxOTdyMx?=
BA/F3	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFjpdZQ4OiCq	NITjbVlFVVOR	NHH4UmRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	MnW2NlM{ODF5MEO=
BA/F3	NWm0d3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVu3NkBp	NELER5pFVVOR	M{P5VGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1?	MWiyN\|MxOTdyMx?=
BA/F3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3T3c\|czKGh?	NE\YVW9FVVOR	NFLYUJdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAyO87:TR?=	MkizNlM{ODF5MEO=
BA/F3	M1Tv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDPRXdEPzJiaB?=	M4rkWmROW09?	MlPMTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0>	NWfXbZA3OjN\|MEG3NFM>
BA/F3	M3G3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH6weoE4OiCq	MoHFSG1UVw>?	MmPQTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1?	MV2yN\|MxOTdyMx?=
BA/F3	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHrr[m44OiCq	NIm0TYNFVVOR	NHHKNVBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIEOuOu69VQ>?	MXiyN\|MxOTdyMx?=
BA/F3	NG\UdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoW3O\|IhcA>?	MnO4SG1UVw>?	MkjMTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42\|ryP	MV:yN\|MxOTdyMx?=
T cell	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPqTYFFPzJiaB?=	M1H5b2ROW09?	NU\kNHhrUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1?	M{TCT\|E4OTV2NUGy
WiDr	M13TOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M37OSVczKGh?	M132WmROW09?	M4PkZmlEPTB;MD6wOVIh\|ryP	MkL5NVU3OTV3MUK=
PC3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXzHWnpWPzJiaB?=	NGDCZnZFVVOR	NYSw[pZQUUN3ME2wMlAxQTRizszN	NITTbGgyPTZzNUWxNi=>
MDA-MB-231	NX;JRVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWG3NkBp	MWDEUXNQ	NFvmXo9KSzVyPUCuNFEzKM7:TR?=	M3fwUFE2PjF3NUGy
Hs578T	MnrDR5l1d3SxeHnjJGF{e2G7		NXO4Z3JXPzJiaB?=	NYLrOJRvTE2VTx?=	NH;PU2RIUTVyPUCuNFMh\|ryP	M2[yZ\|I1ODF3M{K3
HMEC	MXnDfZRwfG:6aXOgRZN{[Xl?		M4XI[FczKGh?	M3PRO2ROW09?	Ml;YS2k2OD1zLkig{txO	NHrY[20zPDBzNUOyOy=>
DU145	M2PlZmN6fG:2b4jpZ{BCe3OjeR?=		NYrGZ\|BJPzJiaB?=	NGnRXW9FVVOR	NFn4bHNIUTVyPUCuNVYh\|ryP	M{LPWFI1ODF3M{K3
U251	Mn\OR5l1d3SxeHnjJGF{e2G7		NV74eo5TPzJiaB?=	NUK4eo1QTE2VTx?=	MmfQS2k2OD1{LkixJO69VQ>?	NFXnNnIzPDBzNUOyOy=>
NCI60	MYfDfZRwfG:6aXOgRZN{[Xl?		MY[3NkBp	MXrEUXNQ	M3PLV2dKPTB;NT63JO69VQ>?	MVqyOFAyPTN{Nx?=
MALME-3M	MoTLR5l1d3SxeHnjJGF{e2G7		M2LwbVczKGh?	MnKySG1UVw>?	NFzGS\|BIUTVyPU[uOlEh\|ryP	MmDaNlQxOTV\|Mke=
KM12	NGDWSZJEgXSxdH;4bYMhSXO\|YYm=		NHvkZok4OiCq	NFXLdXVFVVOR	NVjz[3pQT0l3ME23MlQ1KM7:TR?=	MmjJNlQxOTV\|Mke=
SW620	Mn31R5l1d3SxeHnjJGF{e2G7		NHnqT2w4OiCq	MnXMSG1UVw>?	MWLHTVUxRThwNEOg{txO	NIT1dGYzPDBzNUOyOy=>
RXF 393NL	M16xUmN6fG:2b4jpZ{BCe3OjeR?=		Mmq4OEBl[Xm\|	NG\lUIVFVVOR	M2LkXWlEPTB;MD6wNlE4KM7:TR?=	NVT1R\|U1OjN{NUOwO\|Q>
LXFA 983L	MW\DfZRwfG:6aXOgRZN{[Xl?		NWL3ZppnPCCmYYnz	NF3KUVhFVVOR	M1rVU2lEPTB;MD6wOVY2KM7:TR?=	NX7NWXZXOjN{NUOwO\|Q>
PRXF DU145	M{XkZmN6fG:2b4jpZ{BCe3OjeR?=		MVq0JIRigXN?	MWfEUXNQ	MnHLTWM2OD1yLkC2NlMh\|ryP	NHjKWJYzOzJ3M{C3OC=>
PAXF 1657L	MnHMR5l1d3SxeHnjJGF{e2G7		M17Ee\|Qh\GG7cx?=	NGr4W4RFVVOR	MYrJR\|UxRTBwMUKxJO69VQ>?	M1fkfFI{OjV\|MEe0
CXF 1103L	NYC2OoFoS3m2b4TvfIlkKEG\|c3H5		M4LBe\|Qh\GG7cx?=	MkjrSG1UVw>?	NUftPHRUUUN3ME20MlM3KM7:TR?=	MVWyN\|I2OzB5NB?=
GXF251L	M3HhNGN6fG:2b4jpZ{BCe3OjeR?=		MlXEOEBl[Xm\|	MYDEUXNQ	M1:wUmlEPTB;Mj6yOUDPxE1?	NHnQSJMzOzJ3M{C3OC=>
NCI-H23	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPzUFRYPzJiaB?=	MW\EUXNQ	M3rIPWlEPTB;Mj6yO{DPxE1?	NGnnbpkzOzV{MUCyNC=>
HCT116	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXfFOpNsPzJiaB?=	NEP3SoJFVVOR	NH;2[lBKSzVyPUKuN{DPxE1?	MmTmNlM2OjFyMkC=
MCF7	M{\UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\ib3A4OiCq	M2\WO2ROW09?	Mlz0TWM2OD1{LkW3JO69VQ>?	MoDQNlM2OjFyMkC=
NCI-H460	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYG3NkBp	MknNSG1UVw>?	M4W4[2lEPTB;OD65PUDPxE1?	MlKyNlM2OjFyMkC=
DLD1	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\VVHRoPzJiaB?=	M{i5c2ROW09?	M3y5SWlEPTB;ND62JO69VQ>?	NHvYN4EzOzV4N{m2NC=>
NCI-H661	NYPDWW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUi3NkBp	M2jOUWROW09?	MlfWTWM2OD15Lkig{txO	NU[1NoJlOjN3Nke5OlA>
A549	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHj0cWY4OiCq	NXWxbo5sTE2VTx?=	NXznTIRRUUN3ME24MlIh\|ryP	M{H0S\|I{PTZ5OU[w
U937	NY\Id4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3LWc\|czKGh?	NEn2bIVFVVOR	NGHmO4hKSzVyPUGyMlIh\|ryP	MWeyN\|U3Pzl4MB?=
HEK293	M2LFNWZ2dmO2aX;uJGF{e2G7	NIHnfHoyOMLizszN		M3nnbmROW09?	NGHyUXFKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm\|LYTh[4dm\CCPeYSxJItqdmG\|ZTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB4M988US=>	NFjDbZgzOjd5ME[xNC=>
HUVEC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[1NE4yPcLizszN	MWK3NkBp	NHrabJRFVVOR	NIG3XIVKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0>	M2HyNlIzQDV\|OUmz
HUVEC	NWf1OnhNTnWwY4Tpc44hSXO\|YYm=	M3vEU\|E2yqEQvF2=	NFLuO5o4OiCq	MWnEUXNQ	Ml7GTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0>	MnnGNlI5PTN7OUO=
Plasmodium falciparum	MmTWSpVv[3Srb36gRZN{[Xl?	MkHRNVDDqM7:TR?=	NHjuO3EyPSCvaX6=	MV7EUXNQ	NXTsWIhUUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4\|ryP	NHTBWW8zPDV3MEOzNC=>
PC3	NYLBUXN7TnWwY4Tpc44hSXO\|YYm=	M3LlOVAvOSEQvF2=	MXS1JIg>	NUTzWmNuTE2VTx?=	M4DkVGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	MnjrNVk1PjJ7N{W=
DU145	MkG3SpVv[3Srb36gRZN{[Xl?	NX3ZT5QzOC5zIN88US=>	M4fnRlUhcA>?	NXjVenp7TE2VTx?=	MnfXTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	Ml24NVk1PjJ7N{W=
PC3	NUPYTHZLU2mwYYPlJGF{e2G7	NEj5NmkxNjFizszN	M4LL[\|UhcA>?	M4flbGROW09?	MmnyTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	M1vLXFE6PDZ{OUe1
DU145	MYjLbY5ie2ViQYPzZZk>	NFv2ZXYxNjFizszN	M2TKZ\|UhcA>?	NI\2[2JFVVOR	NUfRVo1[UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O	M4rsS\|E6PDZ{OUe1
PC3	NVf0PHRHU2mwYYPlJGF{e2G7	M{PpRVAvOSEQvF2=	Mk\1OUBp	M1nIS2ROW09?	NEHRbHRKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O\|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?	NWTB[nR2OTl2NkK5O\|U>
DU145	NWHWOpRyU2mwYYPlJGF{e2G7	MWewMlEh\|ryP	NGG5Z4k2KGh?	MWXEUXNQ	NGfX[VdKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?=	NYLQdXRpOTl2NkK5O\|U>
Huh7	NUTaOXhZSW62aY\pdoFtKEG\|c3H5	MUKyMlUh\|ryP	NXrpbZRWPCCmYYnz	NF;HWopFVVOR	MkXDTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	MVKxO\|M3ODZ5Nh?=
C6/36	M{fhRWFvfGm4aYLhcEBCe3OjeR?=	NEDnU5kzNjVizszN	NITQTWQ1KGSjeYO=	NUPPS49XTE2VTx?=	MYnJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO	MXqxO\|M3ODZ5Nh?=
U937	NGTDZWRHfW6ldHnvckBCe3OjeR?=	NHTZW\|YyKM7:TR?=	NH3hXWwyKGh?	M1XzU2ROW09?	NVvIVIhDWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N\|ch[2WubIO=	NV71elV3OTd4OESwPVk>
U937	NV3VUGhwTnWwY4Tpc44hSXO\|YYm=	M3nRflEh\|ryP	M3T6O\|EhcA>?	NIfJWpdFVVOR	MnPyVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	NUH5e2Z2OTd4OESwPVk>
murine mast cell	NHO3dIZHfW6ldHnvckBCe3OjeR?=	NX7hVHQzOSEQvF2=	MYGyOEBp	M4DjeWROW09?	M2f2eGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP	M{LzR\|E4Pjh2MEm5
BV-173	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3r6dWlEPTB;MD6wNFAxODBzMEmg{txO	M4H6N3NCVkeHUh?=
K-562	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTBwMECwNFAxOjZ4IN88US=>	MkHUV2FPT0WU
BL-70	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3lbphKSzVyPUCuNFAxODByOEKyJO69VQ>?	MVzTRW5ITVJ?
EM-2	NEjDWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXHOJNKSzVyPUCuNFAxODBzMEig{txO	NWfuNYtiW0GQR1XS
LAMA-84	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rNZ2lEPTB;MD6wNFAxODN{MTFOwG0>	NVfvO\|BJW0GQR1XS
MEG-01	M3G1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwMECwNFA6QCEQvF2=	NH30XW5USU6JRWK=
EoL-1-cell	NFXh[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXBTWM2OD1yLkCwNFAyOzFizszN	MXzTRW5ITVJ?
CTV-1	NWfYeIdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnDfHZzUUN3ME2wMlAxODB2MESg{txO	NGHVNnNUSU6JRWK=
TE-15	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnZbHRJUUN3ME2wMlAxPTh7IN88US=>	NH\FVmtUSU6JRWK=
NOS-1	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\MeWlEPTB;MD6wNFYyOyEQvF2=	MlnoV2FPT0WU
D-336MG	NY\4WGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3v6N2lEPTB;MD6wNFY{KM7:TR?=	NWS5OFBEW0GQR1XS
LB1047-RCC	NYXjSlM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzVelJKSzVyPUCuNFA6QDlizszN	MUXTRW5ITVJ?
LB996-RCC	M2Tyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnuVo5KSzVyPUCuNFA6QTFizszN	MnfXV2FPT0WU
SW982	M33FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjFV\|BKSzVyPUCuNFEyOTVizszN	NYmwWpNPW0GQR1XS
TK10	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\4enRmUUN3ME2wMlAyOTd2IN88US=>	NEHYT4dUSU6JRWK=
A704	NXTLUms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTBwMEG0PVEh\|ryP	NEn1WHlUSU6JRWK=
TE-8	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml:3TWM2OD1yLkCxOVc3KM7:TR?=	M1;ZWnNCVkeHUh?=
DOHH-2	M2fzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwMEG3NVkh\|ryP	MYjTRW5ITVJ?
HOP-62	M33I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIi1VGhKSzVyPUCuNFE5OzRizszN	NUTzZ4MzW0GQR1XS
TE-12	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTBwMEG4OlEh\|ryP	NF35fIZUSU6JRWK=
KGN	NVHCSZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLRTWM2OD1yLkCxPVQzKM7:TR?=	NE\HN5NUSU6JRWK=
NCI-H1648	M{[4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwMEKwNVEh\|ryP	MX;TRW5ITVJ?
OS-RC-2	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TTR2lEPTB;MD6wNlA{KM7:TR?=	M2qycHNCVkeHUh?=
GB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jPNmlEPTB;MD6wNlE2PyEQvF2=	MX;TRW5ITVJ?
RXF393	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkKwTWM2OD1yLkCyN\|U4KM7:TR?=	MWjTRW5ITVJ?
LC-2-ad	NHjEVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nmZmlEPTB;MD6wNlU5PiEQvF2=	NFnFdIdUSU6JRWK=
KS-1	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwMEK3N{DPxE1?	MXLTRW5ITVJ?
ETK-1	M{mxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnvTWM2OD1yLkCyPFMzKM7:TR?=	MWTTRW5ITVJ?
SW954	NYnuVFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1e2XmlEPTB;MD6wNlkzPyEQvF2=	NX\RT45EW0GQR1XS
Becker	M4PrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDhTWM2OD1yLkCzNFA{KM7:TR?=	NYPzRYN7W0GQR1XS
MZ1-PC	M1y3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMEOxNVkh\|ryP	NGLic3NUSU6JRWK=
ES6	NVyzcm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTBwMEOxPVMh\|ryP	NIDF[4VUSU6JRWK=
KURAMOCHI	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMEO0PFch\|ryP	MWfTRW5ITVJ?
CGTH-W-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vDOGlEPTB;MD6wN\|U1QCEQvF2=	MV\TRW5ITVJ?
VA-ES-BJ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHOTWM2OD1yLkCzPVAzKM7:TR?=	NVTGSnlCW0GQR1XS
LXF-289	NWPne\|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3KfIFLUUN3ME2wMlA{QTV4IN88US=>	M1yzPHNCVkeHUh?=
MPP-89	NVjaNJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfBW3pvUUN3ME2wMlA1ODR7IN88US=>	NWXze\|ZXW0GQR1XS
SW872	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMTJpJUUN3ME2wMlA1OTZzIN88US=>	NF7xcWdUSU6JRWK=
SNB75	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHVOJJKSzVyPUCuNFQ1OzVizszN	M2r5N3NCVkeHUh?=
PSN1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPSTWM2OD1yLkC0OFc1KM7:TR?=	M4XJR3NCVkeHUh?=
LB831-BLC	NYjoSopGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LBOGlEPTB;MD6wOFYxQSEQvF2=	M2jUZ3NCVkeHUh?=
MFH-ino	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTBwMES3NlQh\|ryP	NHjzTZRUSU6JRWK=
TGBC24TKB	NEDQNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HTTWlEPTB;MD6wOFc3OSEQvF2=	Mlf3V2FPT0WU
A388	M3rlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\yTWM2OD1yLkC1NFk2KM7:TR?=	MV\TRW5ITVJ?
BB30-HNC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwMEW0N\|ch\|ryP	MlHaV2FPT0WU
GI-ME-N	NGH3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXnSYZkUUN3ME2wMlA3OTF6IN88US=>	M2PEWnNCVkeHUh?=
TGBC1TKB	NHzDfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\UVXRKSzVyPUCuNFYyPjRizszN	M2\VS3NCVkeHUh?=
TE-10	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHp[VVKSzVyPUCuNFY{PTdizszN	NFPkS5hUSU6JRWK=
A498	NVvwR5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTBwMEeyPFQh\|ryP	M{PW[nNCVkeHUh?=
TE-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjFVJY3UUN3ME2wMlA4QDV6IN88US=>	M4P6dXNCVkeHUh?=
BB65-RCC	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWWzV2ZVUUN3ME2wMlA5OjJ5IN88US=>	Mn;lV2FPT0WU
C2BBe1	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fE[mlEPTB;MD6wPFMxQCEQvF2=	NHz0S3VUSU6JRWK=
NCI-H747	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTBwMEizOlIh\|ryP	MlvIV2FPT0WU
IST-MES1	NV;aWmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwMEi1OVIh\|ryP	NF;t[olUSU6JRWK=
KALS-1	M33mOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfrcXZ6UUN3ME2wMlA6PDlizszN	MUXTRW5ITVJ?
GCIY	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nJUmlEPTB;MD6wPVY2PiEQvF2=	MXTTRW5ITVJ?
RL95-2	NGTI[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILrZlFKSzVyPUCuNVA{QCEQvF2=	M3PzSHNCVkeHUh?=
TE-1	NH;5WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j0OmlEPTB;MD6xNFU1KM7:TR?=	M3H2NnNCVkeHUh?=
NCI-H1355	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j3e2lEPTB;MD6xNVAzQCEQvF2=	MYTTRW5ITVJ?
SW962	NVTEUlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwMUGyPVIh\|ryP	MX7TRW5ITVJ?
KLE	M2nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLjTWM2OD1yLkGxN\|E4KM7:TR?=	NYHIOFhVW0GQR1XS
MC116	NUTuc3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mme4TWM2OD1yLkGxOFEh\|ryP	NXvrfoNGW0GQR1XS
NMC-G1	NUTES3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjuU4tRUUN3ME2wMlEyPjB4IN88US=>	NGnjbWZUSU6JRWK=
KU812	NF;JdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLvTWM2OD1yLkGxPFg{KM7:TR?=	NVvneYszW0GQR1XS
COLO-829	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nIeWlEPTB;MD6xNlIyOyEQvF2=	MV\TRW5ITVJ?
NTERA-S-cl-D1	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnL3TWM2OD1yLkGyNlg{KM7:TR?=	MoHEV2FPT0WU
IST-MEL1	NUS4R5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTBwMUO0OUDPxE1?	NFPobWNUSU6JRWK=
MLMA	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTBwMUSwN\|Ih\|ryP	NFXRTHNUSU6JRWK=
LS-123	M2DHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\KbmlEPTB;MD6xOFA3PCEQvF2=	MnrPV2FPT0WU
LB2518-MEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITMfo9KSzVyPUCuNVQyPjJizszN	MYrTRW5ITVJ?
NB69	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFznNJFKSzVyPUCuNVQ1OzZizszN	NXHUbI1GW0GQR1XS
8-MG-BA	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwMUW0OVgh\|ryP	NWjrUGJFW0GQR1XS
K5	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvCTWM2OD1yLkG2OFg6KM7:TR?=	NGriOWZUSU6JRWK=
KINGS-1	M4HzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnhS5lNUUN3ME2wMlE3PjZ4IN88US=>	M4H1OnNCVkeHUh?=
SF268	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHTVmhKSzVyPUCuNVc1ODRizszN	M1LQSHNCVkeHUh?=
PF-382	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHXTWM2OD1yLkG3Olc5KM7:TR?=	M3:xOnNCVkeHUh?=
SH-4	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETwNJlKSzVyPUCuNVg1OTNizszN	NGPoTIlUSU6JRWK=
NALM-6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLnWZNKSzVyPUCuNVkzQTVizszN	NWLUb3lkW0GQR1XS
CP66-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfuXGdKSzVyPUCuNVk2OzFizszN	NFe0V5dUSU6JRWK=
697	M4rye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMUm5PFch\|ryP	NY\UXmZPW0GQR1XS
CP67-MEL	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXkd4J7UUN3ME2wMlIxPDh6IN88US=>	MWTTRW5ITVJ?
DSH1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwMkSwNFEh\|ryP	MkW5V2FPT0WU
HCE-4	NWPBNItET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrFXmNIUUN3ME2wMlI3PDN7IN88US=>	NH;nSIxUSU6JRWK=
MZ2-MEL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3ZfndKSzVyPUCuNlg2OzdizszN	NFv2coxUSU6JRWK=
BL-41	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwMkmxNlMh\|ryP	NHjjZmFUSU6JRWK=
HUTU-80	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwM{G0NkDPxE1?	MnP2V2FPT0WU
LOXIMVI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nT[mlEPTB;MD6zNVUxOyEQvF2=	Mk\2V2FPT0WU
no-10	NFPPc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHqOXBIUUN3ME2wMlMyQTNzIN88US=>	NHfCcVhUSU6JRWK=
KARPAS-422	NH3BNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHpR4pKSzVyPUCuN\|M6QTdizszN	NHf2cZVUSU6JRWK=
SW684	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofBTWM2OD1yLkO0PVgh\|ryP	MW\TRW5ITVJ?
SF126	NUC0N5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrUUoNKUUN3ME2wMlM2PDFizszN	MUjTRW5ITVJ?
D-263MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HNS2lEPTB;MD6zOlIzPCEQvF2=	NGnPdYNUSU6JRWK=
OVCAR-4	NY\jVlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTid5NKSzVyPUCuN\|c1OzNizszN	MlqwV2FPT0WU
BB49-HNC	NXfCSoNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DR[WlEPTB;MD6zPFU6QSEQvF2=	NYfoXJJoW0GQR1XS
ONS-76	NGHtfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvQTWM2OD1yLkSyPVUyKM7:TR?=	Mkn3V2FPT0WU
MZ7-mel	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDSNIJlUUN3ME2wMlQ4QTFzIN88US=>	M1P5OnNCVkeHUh?=
RCC10RGB	M1rUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\n[GlEPTB;MD60PVEyKM7:TR?=	NVTabodLW0GQR1XS
BOKU	NVvu[3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHXbJFKSzVyPUCuOFkyOzNizszN	NHXGWFBUSU6JRWK=
no-11	M2iweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwNUCyNlgh\|ryP	NEfkfGRUSU6JRWK=
IST-SL2	NX\Ge5JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvibWxyUUN3ME2wMlUxOzB{IN88US=>	MmLNV2FPT0WU
RKO	NYntcFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnEflhLUUN3ME2wMlUzQTZ4IN88US=>	MorWV2FPT0WU
HT-144	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDKTWM2OD1yLkWzOlA6KM7:TR?=	NV7jeJNDW0GQR1XS
NCI-H446	NX;rN4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGGzcmdKSzVyPUCuOlI4PiEQvF2=	Mnz4V2FPT0WU
QIMR-WIL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwN{C2Nlkh\|ryP	NWj4VGVYW0GQR1XS
MHH-PREB-1	NXTjPJZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTBwN{S0Olkh\|ryP	MXzTRW5ITVJ?
EW-16	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XHbGlEPTB;MD63OlE4QCEQvF2=	MnXMV2FPT0WU
EW-24	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTBwN{ixOlUh\|ryP	MmfMV2FPT0WU
LB373-MEL-D	M4HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwOEK1NFgh\|ryP	Ml7YV2FPT0WU
TE-9	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwOEe1N\|Ih\|ryP	Mm\pV2FPT0WU
A3-KAW	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1G2W2lEPTB;MD65PFQ2OiEQvF2=	MnPHV2FPT0WU
A101D	M2m5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn0bFlWUUN3ME2xMlA{ODR\|IN88US=>	M{nqfnNCVkeHUh?=
OCUB-M	NIGwOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFwMES0NVIh\|ryP	M4LMfHNCVkeHUh?=
ES4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFwMEWxOFUh\|ryP	MmLhV2FPT0WU
TE-6	NF:yS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHNTWM2OD1zLkKxNlI3KM7:TR?=	M1rjfXNCVkeHUh?=
D-502MG	M2r3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;UcmlEPTB;MT6yN\|M4PiEQvF2=	MlWzV2FPT0WU
KNS-42	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjTclZoUUN3ME2xMlI1PDF{IN88US=>	MmfVV2FPT0WU
SNU-C2B	NFO5[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;6SWlEPTB;MT6zNFU5QSEQvF2=	MWTTRW5ITVJ?
NCI-H1838	NGjuRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDEfZhKSzVyPUGuN\|A4OzNizszN	MkfiV2FPT0WU
NKM-1	M3juO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37hTGlEPTB;MT6zNFg2QSEQvF2=	MVjTRW5ITVJ?
GI-1	NFL1fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfZe2tMUUN3ME2xMlM3OjJizszN	MmD1V2FPT0WU
NB5	NHG1emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2naXmlEPTB;MT6zPVgzPyEQvF2=	NVnRZll3W0GQR1XS
CAS-1	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnCUJhKUUN3ME2xMlQxQTl{IN88US=>	MYHTRW5ITVJ?
HCE-T	NX;CVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37Zd2lEPTB;MT61OlcyPCEQvF2=	M2nDUnNCVkeHUh?=
SBC-1	NFvXOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PBb2lEPTB;MT61O\|k5PCEQvF2=	M{\BbHNCVkeHUh?=
JiyoyeP-2003	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HLOmlEPTB;MT63N\|Q3PiEQvF2=	NIfWc5NUSU6JRWK=
TE-5	M3fCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv6TWM2OD1zLke5NVM6KM7:TR?=	NXPhSHgyW0GQR1XS
CAN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvhfnVKSzVyPUGuPFIzPTJizszN	NYC5[4tqW0GQR1XS
SK-UT-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC0NphCUUN3ME2yMlE3Pjl\|IN88US=>	M3LYZ3NCVkeHUh?=
JVM-2	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HvXWlEPTB;Mj6zOlI5PCEQvF2=	M{joXnNCVkeHUh?=
LB771-HNC	M3\iTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnhTmVKSzVyPUKuOVc2PTFizszN	MVXTRW5ITVJ?
NCCIT	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrCTnFKSzVyPUKuPFY3OTZizszN	MnTVV2FPT0WU
NCI-H2126	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjIRo1KSzVyPUKuPFc2PTJizszN	MlLnV2FPT0WU
Calu-6	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;LUpRKSzVyPUOuNFU4PDFizszN	NYDSOG5WW0GQR1XS
SK-LMS-1	NV2yeXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j0O2lEPTB;Mz6xNVg5PiEQvF2=	NXrOdZoxW0GQR1XS
ARH-77	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XtPWlEPTB;Mz60OlkyPSEQvF2=	MXnTRW5ITVJ?
NB17	NWXuRY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS3O2lkUUN3ME2zMlY{QDR5IN88US=>	NHu5NHhUSU6JRWK=
A253	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfkUlRlUUN3ME2zMlc{OjR4IN88US=>	M1LnOnNCVkeHUh?=
OPM-2	NH6zSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL1TWM2OD12LkK3Olg2KM7:TR?=	M{HUbHNCVkeHUh?=
MV-4-11	NHn5N2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fVbWlEPTB;ND6zOlQ2PCEQvF2=	NW\KeWZJW0GQR1XS
SR	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3flUmlEPTB;ND60PVk2PCEQvF2=	MXLTRW5ITVJ?
KG-1	NWKzR3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTRwNkC4OFUh\|ryP	M2nEZXNCVkeHUh?=
OCI-AML2	NHXadItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTVwOE[xOVQh\|ryP	MUDTRW5ITVJ?
D-247MG	NIi4dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfKTWFKSzVyPU[uNVI2OTlizszN	M2iyRnNCVkeHUh?=
DJM-1	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HzTGlEPTB;Nj60PFU2QCEQvF2=	Mn;JV2FPT0WU
RPMI-6666	M3zjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni2TWM2OD15LkK3NFY4KM7:TR?=	MWPTRW5ITVJ?
KARPAS-45	NGXQdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vVR2lEPTB;Nz61NVY4OSEQvF2=	MU\TRW5ITVJ?
LP-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULMTplXUUN3ME23MlU1Pzh{IN88US=>	NUTWfI9YW0GQR1XS
RS4-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUH4[G1uUUN3ME23MlY2Pzh5IN88US=>	MlnkV2FPT0WU
DU-4475	M3rkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD4SXU4UUN3ME24MlIyPjV{IN88US=>	NFzRRpBUSU6JRWK=
MONO-MAC-6	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorjTWM2OD16LkK3NFY3KM7:TR?=	MWfTRW5ITVJ?
NCI-SNU-16	NHjDTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRThwNU[xNlgh\|ryP	MnX0V2FPT0WU
SJSA-1	NFf6XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXz6NIkzUUN3ME24MlczQDB3IN88US=>	MkPPV2FPT0WU
MMAC-SF	NUTFbplxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\kTWM2OD16Lke5N\|A4KM7:TR?=	NV7qNWJGW0GQR1XS
SK-NEP-1	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorwTWM2OD16Lki5NVU2KM7:TR?=	MWfTRW5ITVJ?
J-RT3-T3-5	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRThwOU[1Nlkh\|ryP	NUKxZXlvW0GQR1XS
SKM-1	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;3OpdpUUN3ME25MlAyPzN2IN88US=>	NIrQZ25USU6JRWK=
LB2241-RCC	NUDvRYxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fGd2lEPTB;OT6wNlAyOiEQvF2=	MlHQV2FPT0WU
SIG-M5	NGXEWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnSdYpiUUN3ME25MlAzPDl\|IN88US=>	NHzyOZBUSU6JRWK=
EVSA-T	NHnmc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzVdWR4UUN3ME25MlI4Pzl\|IN88US=>	NIKwXZFUSU6JRWK=
GT3TKB	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L1NWlEPTB;OT6zOVU1PiEQvF2=	MojEV2FPT0WU
NB6	M3z5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DlNGlEPTB;OT65NlI2QSEQvF2=	NXvSSnhQW0GQR1XS
EHEB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIL0OldKSzVyPUGwMlA3PTZizszN	M3rKO3NCVkeHUh?=
HEL	NVzHbVJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HsSmlEPTB;MUCuOFc4PiEQvF2=	NUL0ZZZnW0GQR1XS
ALL-PO	NYjEVHJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPyOppKSzVyPUGwMlc6OzhizszN	Mki5V2FPT0WU
TGW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3P3ZWlEPTB;MUGuNlgzQCEQvF2=	M4PTdnNCVkeHUh?=
BC-3	NUTienI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2W4SWlEPTB;MUKuNVE{QCEQvF2=	MXvTRW5ITVJ?
IA-LM	NEDoUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonvTWM2OD1zMj60OFQ2KM7:TR?=	NHXxTlhUSU6JRWK=
UACC-257	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPl[\|RKSzVyPUGyMlkyQThizszN	NGS2epVUSU6JRWK=
KP-N-YS	M1;2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rKPGlEPTB;MUKuPVI5OyEQvF2=	NUW3cFhVW0GQR1XS
Raji	NXLDXHBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\CeWlEPTB;MUOuO\|Q6PyEQvF2=	M4m4UHNCVkeHUh?=
SF539	M3HGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDLOpVKSzVyPUGzMlg2PTdizszN	NGLGXm5USU6JRWK=
DMS-153	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXWWW5sUUN3ME2xOE4xODJ6IN88US=>	NYHLSFUxW0GQR1XS
L-540	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTF3LkC2O\|Ih\|ryP	Ml7yV2FPT0WU
MN-60	NUHvNodpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXXPJlKSzVyPUG1MlE6PzlizszN	MlLKV2FPT0WU
RPMI-8866	NITzNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3uemdYUUN3ME2xO{41PDV2IN88US=>	MY\TRW5ITVJ?
NCI-H510A	NFPNT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\HZnRKSzVyPUG5MlM6PzNizszN	NYrRflg{W0GQR1XS
NB13	NES3R4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7aSYlNUUN3ME2xPU41QDd5IN88US=>	MXTTRW5ITVJ?
HAL-01	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnTXFdQUUN3ME2xPU44PTR\|IN88US=>	M{fmRnNCVkeHUh?=
NCI-H720	NGjsUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrlTWM2OD1{MD6yO\|M{KM7:TR?=	M13ZTnNCVkeHUh?=
REH	NVXyW2JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn2[45RUUN3ME2yNE43OzV5IN88US=>	NEnzcWVUSU6JRWK=
KNS-81-FD	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDucoNKSzVyPUKzMlE1PiEQvF2=	NEPjVJdUSU6JRWK=
HC-1	M2HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rZWmlEPTB;MkSuOVU2OSEQvF2=	MX7TRW5ITVJ?
NCI-H2141	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHuRVE4UUN3ME2yOE44PzV2IN88US=>	M4HscXNCVkeHUh?=
MOLT-4	NGjD[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Hld2lEPTB;Mk[uOlc2OyEQvF2=	NWr1Tod1W0GQR1XS
OMC-1	M173XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJ5LkG0NlIh\|ryP	NInZT3ZUSU6JRWK=
LC-1F	NV7iSXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P5V2lEPTB;MkeuN\|I1PSEQvF2=	NVvQdoYzW0GQR1XS
NCI-H1304	NWrjSIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjEOlVWUUN3ME2yPE4yPjJ6IN88US=>	NUHJO2R6W0GQR1XS
BC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\1fYhwUUN3ME2yPE43PTFizszN	NXTyXY92W0GQR1XS
NCI-H64	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfGTWM2OD1{OT62NlU{KM7:TR?=	MVHTRW5ITVJ?
MOLT-16	M{D2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LEbmlEPTB;MkmuOlI6OiEQvF2=	M{i4dXNCVkeHUh?=
U-87-MG	M2rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrReFZlUUN3ME2zNE44PjZizszN	NWHRPHUzW0GQR1XS
GAK	NWqxdmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo[2TWM2OD1\|MT6yOlg3KM7:TR?=	M2TFW3NCVkeHUh?=
ES8	NELqepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PTfGlEPTB;M{KuNVI2OiEQvF2=	M1THT3NCVkeHUh?=
HCC1599	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXwTWM2OD1\|Mj6zN\|I2KM7:TR?=	NVHRRYN1W0GQR1XS
EB-3	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTN2LkOxNVch\|ryP	MVfTRW5ITVJ?
HCC1187	NIHP[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3e3TGlEPTB;M{WuPFA2OiEQvF2=	NW\NfJFoW0GQR1XS
SK-PN-DW	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;WfJVKSzVyPUO2MlE6PDNizszN	MnPMV2FPT0WU
JVM-3	NHzq[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XU[WlEPTB;M{euNlM{QCEQvF2=	NEDTZ3RUSU6JRWK=
HCC2157	NFHTOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3j0Z2lEPTB;M{euPVk1PiEQvF2=	NHTNfYVUSU6JRWK=
A4-Fuk	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M170WmlEPTB;M{iuNVAxQSEQvF2=	NWXu[IZ1W0GQR1XS
COR-L279	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnScJU5UUN3ME20NE4zQDVzIN88US=>	MVnTRW5ITVJ?
DEL	M1\6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfqRYdKUUN3ME20NU46ODh4IN88US=>	NIfXenJUSU6JRWK=
NCI-H1395	NVS1SGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTR{LkCxOlMh\|ryP	NGPqWoNUSU6JRWK=
MHH-NB-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\hSmlEPTB;NEOuNFgyQCEQvF2=	NWfEO3R6W0GQR1XS
NCI-H2107	NXjPNVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjoTWM2OD12Mz60PFQ3KM7:TR?=	NILkR3FUSU6JRWK=
NEC8	M2ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUC5NJB4UUN3ME20OE4{OzZizszN	M{LFOHNCVkeHUh?=
COLO-684	NX7acJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTR4LkKyOVgh\|ryP	NYHmdWx3W0GQR1XS
LS-411N	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHKSGFKSzVyPUS4MlQ4PDhizszN	MoXpV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	+ 展开激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	+ 展开 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

+ 展开

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	BMS-354825

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03885830	Not yet recruiting	CML Chronic Phase\|CML (Chronic Myelogenous Leukemia\|CML - Philadelphia Chromosome\|Chronic Myeloid Leukemia\|Chronic Myeloid Leukemia Chronic Phase	UNC Lineberger Comprehensive Cancer Center	May 2019	--
NCT03885830	Not yet recruiting	CML Chronic Phase\|CML (Chronic Myelogenous Leukemia\|CML - Philadelphia Chromosome\|Chronic Myeloid Leukemia\|Chronic Myeloid Leukemia Chronic Phase	UNC Lineberger Comprehensive Cancer Center	May 2019	--
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
回答：
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
问题 2：
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
回答：
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

泛Src抑制剂

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

Dasatinib

客户使用Selleck该产品发表文献76篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dasatinib SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品